• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

2017 ADA Standards of Medical Care: Evidence-based Updates

Slideshow

Cardioprotection, diabetes anxiety, and hypoglycemia protection are just a few of the areas amended with new guidance.

The American Diabetes Association's newly revised 2017 Standards of Medical Care in Diabetes include updated recommendations in several domains essential to management of diabetes across the continuum of care. In ongoing recognition of the prevasive impact of diabetes on patients' lives, evidence-based additions have been made under the categories of psychosocial care, nutrition therapy and physical fitness, metabolic surgery, and management of hypoglycemia, among others.These and other revisions and updates are highlighted in the slides above. The full text of the Standards are available in the January 2017 issue of Diabetes Care.

References:

ADA Standard of Medical Care in Diabetes. Diabetes Care.  2017; 40(S1). Accessed January 27 2017 at  http://care.diabetesjournals.org/content/40/Supplement_1

ADA 2017 Standards of Medical Care: Summary of Revisions. 2017;40 (S1):S4-S5.  Accessed January 27, 2017 at: http://care.diabetesjournals.org/content/40/Supplement_1/S4

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.